VISEN Pharma Sets 27 Aug 2026 Board Meeting to Approve H1 2026 Interim Results

Bulletin Express

Aug 17

VISEN Pharmaceuticals has notified investors that its board will convene on 27 August 2026 to review and approve the interim financial results for the six months ended 30 June 2026. The meeting will also address other routine corporate matters.

The notice, dated 17 August 2026, was signed by Executive Director and Chief Executive Officer Mr. Lu An-Bang. VISEN’s current board comprises one executive director (Mr. Lu), five non-executive directors (Mr. Fu Shan, Mr. Cao Yibo, Mr. Roy Paul Khoury, Ms. Sherrie Lynn Glass and Mr. Michael J. Chang) and four independent non-executive directors (Dr. Yao Zhengbin, Mr. Chan Peng Kuan, Ms. Ni Hong and Mr. Zhang Qing).

The forthcoming board meeting will determine the company’s official H1 2026 financial disclosure timeline and content, providing the market with an update on VISEN Pharma’s operational and financial performance for the period.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1159299738"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1159299738\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1159299738?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-17 16:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1159299738","market":"us","top_or_hot":-1,"title":"VISEN Pharma Sets 27 Aug 2026 Board Meeting to Approve H1 2026 Interim Results","media":"Bulletin Express","content":"<p>VISEN Pharmaceuticals has notified investors that its board will convene on 27 August 2026 to review and approve the interim financial results for the six months ended 30 June 2026. The meeting will also address other routine corporate matters.</p>\n<p>The notice, dated 17 August 2026, was signed by Executive Director and Chief Executive Officer Mr. Lu An-Bang. VISEN’s current board comprises one executive director (Mr. Lu), five non-executive directors (Mr. Fu Shan, Mr. Cao Yibo, Mr. Roy Paul Khoury, Ms. Sherrie Lynn Glass and Mr. Michael J. Chang) and four independent non-executive directors (Dr. Yao Zhengbin, Mr. Chan Peng Kuan, Ms. Ni Hong and Mr. Zhang Qing).</p>\n<p>The forthcoming board meeting will determine the company’s official H1 2026 financial disclosure timeline and content, providing the market with an update on VISEN Pharma’s operational and financial performance for the period.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>VISEN Pharma Sets 27 Aug 2026 Board Meeting to Approve H1 2026 Interim Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVISEN Pharma Sets 27 Aug 2026 Board Meeting to Approve H1 2026 Interim Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-08-17 16:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>VISEN Pharmaceuticals has notified investors that its board will convene on 27 August 2026 to review and approve the interim financial results for the six months ended 30 June 2026. The meeting will also address other routine corporate matters.</p>\n<p>The notice, dated 17 August 2026, was signed by Executive Director and Chief Executive Officer Mr. Lu An-Bang. VISEN’s current board comprises one executive director (Mr. Lu), five non-executive directors (Mr. Fu Shan, Mr. Cao Yibo, Mr. Roy Paul Khoury, Ms. Sherrie Lynn Glass and Mr. Michael J. Chang) and four independent non-executive directors (Dr. Yao Zhengbin, Mr. Chan Peng Kuan, Ms. Ni Hong and Mr. Zhang Qing).</p>\n<p>The forthcoming board meeting will determine the company’s official H1 2026 financial disclosure timeline and content, providing the market with an update on VISEN Pharma’s operational and financial performance for the period.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02561","symbol_name":"维升药业-B","start_time":0,"source_url":"","article_id":"1159299738","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1159299738","pubTimestamp":1786956363,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"VISEN Pharmaceuticals has notified investors that its board will convene on 27 August 2026 to review and approve the interim financial results for the six months ended 30 June 2026. The meeting will...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02561":"维升药业-B"},"translate_title":"VISEN Pharma 定于 2026 年 8 月 27 日召开董事会会议，批准 2026 年上半年中期业绩","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02561":1},"content_text":"VISEN Pharmaceuticals has notified investors that its board will convene on 27 August 2026 to review and approve the interim financial results for the six months ended 30 June 2026. The meeting will also address other routine corporate matters.\nThe notice, dated 17 August 2026, was signed by Executive Director and Chief Executive Officer Mr. Lu An-Bang. VISEN’s current board comprises one executive director (Mr. Lu), five non-executive directors (Mr. Fu Shan, Mr. Cao Yibo, Mr. Roy Paul Khoury, Ms. Sherrie Lynn Glass and Mr. Michael J. Chang) and four independent non-executive directors (Dr. Yao Zhengbin, Mr. Chan Peng Kuan, Ms. Ni Hong and Mr. Zhang Qing).\nThe forthcoming board meeting will determine the company’s official H1 2026 financial disclosure timeline and content, providing the market with an update on VISEN Pharma’s operational and financial performance for the period.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"conferences,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}